Skip to main content
SpringerLink
Log in

Establishment of a Medical System with HBOC in Mind

  • Chapter
  • First Online:
Practical Guide to Hereditary Breast and Ovarian Cancer

  • 108 Accesses

Abstract

It has been reported that 5–10% of breast cancers are hereditary, and about half of all hereditary breast cancer are hereditary breast and ovarian cancer (HBOC), which is caused by BRCA1 (breast cancer susceptibility gene 1) and BRCA2 (breast cancer susceptibility gene 2) mutations. When HBOC is identified in breast cancer patients, the prevention and treatment options include prophylactic surgery of the breast and ovary, screening for contralateral breast cancer with annual breast magnetic resonance imaging (MRI) surveillance, use of poly (ADP-ribose) polymerase (PARP) inhibitors, and genetic testing of relatives. Therefore, HBOC should be considered when treating breast cancer patients, and genetic testing should be suggested for patients who need BRCA1/2 gene testing. Once BRCA mutation is identified, it is necessary to support patients’ decision-making by providing information from multiple disciplines. The establishment of a surveillance system for BRCA1/2 mutation carriers who do not develop breast cancer will be an issue for future consideration.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.

    Article  Google Scholar 

  2. Tung N, Lin NU, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol. 2016;34(13):1460–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004;95(11):866–71.

    Article  CAS  PubMed  Google Scholar 

  4. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329–33.

    Article  PubMed  Google Scholar 

  5. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402–16.

    Article  CAS  PubMed  Google Scholar 

  6. Nyberg T, Frost D, Barrowdale D, et al. Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Eur Urol. 2020;77(1):24–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996;56(23):5360–4.

    CAS  PubMed  Google Scholar 

  8. Iqbal J, Ragone A, Lubinski J, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2012;107(12):2005–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66–71.

    Article  CAS  PubMed  Google Scholar 

  10. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789–92.

    Article  CAS  PubMed  Google Scholar 

  11. Cropper C, Woodson A, Arun B, et al. Evaluating the NCCN clinical criteria for recommending BRCA1 and BRCA2 genetic testing in patients with breast cancer. J Natl Compr Cancer Netw. 2017;15(6):797–803.

    Article  CAS  Google Scholar 

  12. George A. UK BRCA mutation testing in patients with ovarian cancer. Br J Cancer. 2015;113 Suppl 1(Suppl 1):S17–21.

    Article  PubMed  Google Scholar 

  13. Forbes C, Fayter D, de Kock S, Quek RG. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer. Cancer Manag Res. 2019;11:2321–37.

    Article  PubMed  PubMed Central  Google Scholar 

  14. National Comprehensive Cancer Netwok Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 2.2022 — March 9, 2022.

    Google Scholar 

  15. Yadav S, Hu C, Hart SN, et al. Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer. J Clin Oncol. 2020;38(13):1409–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. ESMO Prevention and Screening in BRCA Mutation Carriers and Other Breast/ovarian Hereditary Cancer Syndromes Guideline. http://interactiveguidelines.esmo.org/esmo-web-app/gl_toc/index.php?GL_id=53. Accessed 22 May 2022

  17. Guidebook for Diagnosis and Treatment of Hreditary Breast and Ovarian Cancer Syndrome; 2017. http://johboc.jp/guidebook2017/toc/2-1index/cq1/. Accessed 29 May 2022

  18. Guo F, Scholl M, Fuchs EL, Berenson AB, Kuo YF. BRCA testing and testing results among women 18-65 years old. Prev Med Rep. 2022;26:101738.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Sun L, Cui B, Wei X, et al. Cost-effectiveness of genetic testing for all women diagnosed with breast cancer in China. Cancers (Basel). 2022;14(7)

    Google Scholar 

  20. Evans DG, Ingham SL, Baildam A, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat. 2013;140(1):135–42.

    Article  CAS  PubMed  Google Scholar 

  21. Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015;136(3):668–77.

    Article  CAS  PubMed  Google Scholar 

  22. Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348:g226.

    Article  PubMed  PubMed Central  Google Scholar 

  23. van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005;93(3):287–92.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Brekelmans CT, Seynaeve C, Menke-Pluymers M, et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol. 2006;17(3):391–400.

    Article  CAS  PubMed  Google Scholar 

  25. Xiao YL, Wang K, Liu Q, Li J, Zhang X, Li HY. Risk reduction and survival benefit of risk-reducing Salpingo-oophorectomy in hereditary breast cancer: meta-analysis and systematic review. Clin Breast Cancer. 2019;19(1):e48–65.

    Article  PubMed  Google Scholar 

  26. Guindalini RSC, Zheng Y, Abe H, et al. Intensive surveillance with biannual dynamic contrast-enhanced magnetic resonance imaging downstages breast cancer in BRCA1 mutation carriers. Clin Cancer Res. 2019;25(6):1786–94.

    Article  PubMed  Google Scholar 

  27. Riedl CC, Luft N, Bernhart C, et al. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol. 2015;33(10):1128–35.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292(11):1317–25.

    Article  CAS  PubMed  Google Scholar 

  29. Evans DG, Kesavan N, Lim Y, et al. MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Res Treat. 2014;145(3):663–72.

    Article  PubMed  Google Scholar 

  30. Chéreau E, Uzan C, Balleyguier C, et al. Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging. Clin Breast Cancer. 2010;10(2):113–8.

    Article  PubMed  Google Scholar 

  31. Evans DG, Harkness EF, Howell A, et al. Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality. Hered Cancer Clin Pract. 2016;14:8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Japanese Organization of Heredity Breast and Ovarian Cancer. Guidelines for Diagnosis and Treatment of Hreditary Breast and Ovarian Cancer; 2021.

    Google Scholar 

  33. Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31(14):1748–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Na R, Zheng SL, Han M, et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol. 2017;71(5):740–7.

    Article  CAS  PubMed  Google Scholar 

  35. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–34.

    Article  CAS  PubMed  Google Scholar 

  36. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109–15.

    Article  CAS  PubMed  Google Scholar 

  37. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–33.

    Article  CAS  PubMed  Google Scholar 

  38. Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394–405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281(23):2189–97.

    Article  CAS  PubMed  Google Scholar 

  40. Lippman ME, Cummings SR, Disch DP, et al. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res. 2006;12(17):5242–7.

    Article  CAS  PubMed  Google Scholar 

  41. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381(9880):1827–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652–62.

    Article  CAS  PubMed  Google Scholar 

  43. DeCensi A, Puntoni M, Guerrieri-Gonzaga A, et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. J Clin Oncol. 2019;37(19):1629–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Xu L, Zhao Y, Chen Z, Wang Y, Chen L, Wang S. Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis. Breast Cancer. 2015;22(4):327–34.

    Article  CAS  PubMed  Google Scholar 

  45. Hu C, Hart SN, Gnanaolivu R, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med. 2021;384(5):440–51.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Momozawa Y, Iwasaki Y, Parsons MT, et al. Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nat Commun. 2018;9(1):4083.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Breast Surgical Oncology, Department of Surgery, Showa University, Tokyo, Japan

    Rika Narui, Kanae Taruno & Seigo Nakamura

Authors
  1. Rika Narui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kanae Taruno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seigo Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rika Narui .

Editor information

Editors and Affiliations

  1. Akasaka Sanno Medical Center, International University of Health and Welfare Graduate School, Minato-ku, Tokyo, Japan

    Daisuke Aoki

  2. Department of Breast Surgical Oncology, Showa University, School of Medicine, Shinagawa-ku, Tokyo, Japan

    Seigo Nakamura

  3. Research and Development Center for Precision Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan

    Yoshio Miki

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Narui, R., Taruno, K., Nakamura, S. (2023). Establishment of a Medical System with HBOC in Mind. In: Aoki, D., Nakamura, S., Miki, Y. (eds) Practical Guide to Hereditary Breast and Ovarian Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-99-5231-1_1

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-5231-1_1

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-5230-4

  • Online ISBN: 978-981-99-5231-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation